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Summary An analysis of prognostic factors in small cell lung cancer has been made using presentation data
from 86 of 101 consecutive patients referred to The Finsen Institute for chemotherapy. Prognosis was in
univariate analysis significantly correlated with performance status (PS), disease extent, serum lactate
dehydrogenase (LDH), neuron specific enolase (NSE), alpha-l-acid glycoprotein and plasma sodium.
Multivariate analysis, taking stage of disease into account, resulted in selection of PS and NSE as the most
influential of the investigated variables. LDH was excluded as an independent prognosticator, but there was a
strong correlation between the influence of LDH and NSE (coefficient: -0.38) as well as between their serum
concentrations (coefficient: 0.72). LDH and NSE apparently have similar prognostic influence, and NSE
seems superior to LDH. A firm conclusion should, however, await our investigation of a large series of
patients.
Prognostic factors with a well documented significance for
survival in patients with small cell lung cancer (SCLC)
include performance status (PS), extent of disease, serum
lactate dehydrogenase (LDH), serum alkaline phosphatase
(AP), plasma sodium (Na) and age (Souhami et al., 1985,
0sterlind & Andersen, 1986, Cerny et al., 1987, Vincent et
al., 1987). These variables have all been assessed in multivar-
iate analysis.
With respect to tumour markers serum neuron specific
enolase (NSE), carcinoembryonic antigen (CEA) and alpha-l-
acid glycoprotein (AGP) have separately been found import-
ant for the prognosis. A negative correlation was described
between initial high or low levels of NSE and survival
(Akoun et al., 1985). Contradictory results have been found
for CEA (Sculier et al., 1985, Bucceri et al., 1987), while a
normalization of serum AGP level during chemotherapy
involved a longer disease-free survival (Ganz et al., 1984).
These investigations on tumour markers are based on
univariate analysis which limits the conclusions to be drawn.
Accordingly, the present study was performed using a
multivariate analysis. The aim was to assess the prognostic
significance on survival of the above mentioned tumour
markers and compare their influence with that of already
well established prognostic factors.
Methods and materials
Patients
From a consecutive series of 101 patients with histologically
proven SCLC, referred to The Finsen Institute for chemoth-
erapy, 86 patients were entered into the study. The residual
15 patients were excluded because they lacked some of the
pretreatment blood samples. Pretreatment staging procedures
included clinical examination, chest X-ray, bronchoscopy,
bilateral bone marrow biopsies, liver ultrasound or perito-
neoscopy with biopsy of the liver in order to verify metasta-
tic disease histologically. In accordance with the
recommendation of The Veterans Administration Lung
Cancer Study Group (Zelen, 1973) the disease was classified
as limited (LD), if the tumour was confined to one hemith-
orax including ipsilateral supraclavicular nodes or as exten-
sive (ED), if the tumour had spread beyond these limits.
Performance status was evaluated according to the WHO
criteria (WHO, 1979). The pretreatment characteristics of the
patients are listed in Table I.
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Treatment
Patients received combination chemotherapy including cis-
platinum, etoposide, vincristine, and lomustine (Osterlind et
al., 1986; Pedersen et al., 1987).
Tumour marker assessment
Serum NSE was measured by a radioimmunoassay (NSE-
RIA, Pharmacia Diagnostics AB, Uppsala, Sweden), serum
CEA by the Amerwell CEA-RIA (Amersham International
Amersham, Bucks, UK) and serum alpha-l-acid glycoprotein
by radial immunodiffusion using antisera obtained from
Daco, Copenhagen, Denmark. The following values were
regarded as normal limits of the bio-markers:
NSE<12.5ngml-1, CEA<5.Ongml-1 and AGP<1.4gl-1.
In addition to these 3 tumour markers the following vari-
ables were included in the prognostic factor analysis: serum
LDH and AP, plasma sodium, age, sex, PS and disease
stage. The cut-off values used for routinely measured bioche-
mical samples were our laboratory's normal limits of these
variables.
Statistical methods
The prognostic influence of each variable was first investi-
gated in univariate analysis. A significance level of P<0.05
was applied. Survival in different categories based on the
individual variable were studied by use of life tables and
compared by log rank analysis (Peto et al., 1977). The test
for trend (Tarone, 1975) was used in variables enabling a
ranking of patients into more than two groups. Continuous
variables such as LDH, NSE, AP, AGP and CEA were
categorized as 'O' if normal while raised values were categor-
ized by the factor of increase, maximally '3'. In NSE the cut-
off levels were: 12.5ngml-1, 50.Ongml-1 and 90.Ongml-1.
Cox's proportional hazards model was applied for the
multiple regression analysis (Cox, 1972). A backward step-
wise elimination procedure was used and estimation of
regression coefficients was based on the maximum likelihood
method. Exclusions of variables from the model were based
on the partial likelihood ratios test (Andersen & Waeth,
1984). The BMDP statistical software package was used for
the analyses (Berkeley, 1981).
Results
The pretreatment characteristics are listed in Table I. The
median duration of follow-up of all patients was 308 days
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Table I Pretreatment characteristics in 86 patients with SCLC
Females
PS: 0
1
2-4
Stage: LD
N=49
33%
39%
47%
14%
100- Stage: ED
N=37
27%
11%
34%
46%
Mean Range Mean Range
Age (years)
LDH (Ul - 1)
AP (Ul-1)
NSE (ngml-1)
CEA (ngml-1)
AGP (gI-1)
Na (mmol -')
60
430
240
25.2
8.3
1.54
137
41-73
218-929
126-447
3.3-96.7
0.3 -88.9
0.32-3.80
117-143
61
898
548
77.3
19.6
1.85
137
38-73
253-4640
102-2980
6.7-285.0
0.1-121.0
0.5-3.80
114-152
(range: 2-791 days). Sixteen patients were alive, when the
analyses were performed.
Results of the log rank analysis and the test for trend are
summarized in Table II. PS, extent of disease, LDH, NSE,
AGP and Na all had significant influence on survival. The
test for trend gave the highest score for NSE followed by
LDH and PS. Survival curves in groups based on NSE are
shown in Figure 1. The median durations of survival in these
groups were 95, 230, 325 and 656 days, respectively.
PS>2 was significantly related to a poorer prognosis.
Twelve patients with PS 3 or 4 achieved a median survival of
5.5 weeks. Neither AP, CEA, age nor sex were found
significantly related to survival.
All variables were included in a multivariate model and
those with insignificant influence were excluded stepwise.
The continuous variables were categorized into the same
four groups as in the test for trend. Death hazards in
patients with limited and extensive stage disease were not
proportional and a model stratified for stage was therefore
chosen as the best fit for the data.
Only NSE and PS remained as significant prognostic
factors in the final model. A test of interaction between the
two variables resulted in a tendency for a stronger influence
of NSE in good performance, but the effect was not
significant. LDH had significant influence, if NSE was
excluded during the stepwise reduction of the model. When
both remained in the model the correlation coefficient
between the influence of the two variables was -0.38. A
scatter diagram of NSE with LDH revealed a correlation
coefficient of 0.72 between concentrations of the two bioche-
mical entities (Figure 2).
Discussion
By multiple regression analysis NSE and PS were selected as
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Figure 1 Survival for 4 categories based on NSE, including 20,
38, 16 and 12 patients, respectively.
the most determinant variables for survival in SCLC. To our
knowledge an investigation comparing the influence of NSE
with that of well established prognostic factors has not
previously been reported, neither has prognostic stratifica-
tion based on this variable. Our results disclosed significantly
decreasing survival duration from group to group in the four
groups based on serum NSE.
The prognostic impact of pre-treatment PS in SCLC is
well known from a number of multivariate analysis in large
series (Lanzotti et al., 1977, Stanley, 1980, Souhami et al.,
1985, 0sterlind & Andersen, 1986, Cerny et al., 1987,
Vincent et al., 1987). The Veterans Administration lung
study group evaluated 77 possible prognostic factors in 5,000
patients. After regression analysis three were significant: PS,
stage of disease and prior weight loss. The two early
investigations from 1977 and 1980, unfortunately, include
both patients with non-SCLC and with SCLC. There may,
furthermore, be some histological discrepancies, as both
studies are dated before 1981 when the current guidelines for
histological classification of bronchogenic tumours was pub-
lished (WHO, 1981). The four series published in 1985-87
were restricted to patients with SCLC and all proved the
importance of PS.
Our observation of strong relationship between both the
serum levels of NSE and LDH (correlation coefficient=0.72)
Table II Survival duration: Influence of pretreatment variables
LRT TT LRT TT
Variable Weeks? N X2 x2 P P
Extend: LD vs. ED 61 34 49 37 15.73 - <0.0005
PS: 0+1 vs. 2-4 6040 62 24 14.23 23.54 <0.0005 <0.0005
Age: <63, >63yrs. 44 44 41 45 0.10 0.35 NS NS
M vs. F 40 62 60 26 0.64 NS -
LDH: <450, >450 65 34 41 43 16.02 29.89 <0.0005 <0.0005
NSE: <12.5, > 12.5 78 38 20 66 10.93 30.80 <0.001 <0.0005
AGP: <1.40, >1.40 66 38 35 51 8.54 11.69 <0.005 <0.001
Na: <135, >135 50 38 18 61 3.99 1.30 <0.05 NS
AP: <275, >275 50 38 52 30 1.57 5.65 NS <0.025
CEA: <5.0, >5.0 48 40 48 38 2.23 4.46 NS <0.05
a: Median duration; N: Number examined; LRT: Log rank test; TT: Test for
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Table III Results of Cox's proportional hazards
regression analysis in 86 patients with SCLC
Regression
Variable coefficient SE P
NSE 0.517 0.159 <0.001
PS 0.408 0.130 <0.001
The regression model is stratified into limited
and extensive stage disease because of insufficient
proportionality of death hazards between the two
stages.
and their influence on survival (-0.38) indicates that the
two variables may contain similar information and supports
the role of NSE as an apparently important prognostic
factor. Once NSE was included in he model, LDH did not
provide additional significant information.
Significant prognostic influence of LDH has been con-
firmed by two recent series. Thus Osterlind & Andersen
(1986) found major influence of LDH among 18 variables in
778 cases, and LDH was also among the six most important
variables among 60 investigated features in a study on 407
patients (Cerny et al., 1987).
Our CEA measurements were not related to survival. The
conflicting results of the prognostic influence of CEA (Scu-
lier et al., 1985, Buccheri et al., 1987) may be derived from
differences in methods and variables included in the investi-
gation, and we suspect that CEA has only inferior influence
on the prognosis in SCLC.
We could not confirm the importance of AP described by
Souhami et al. (1985) and by Vincent et al. (1987). None of
the two studies did, however, include LDH in the analysis.
Na, AGP, age and sex did not add critical information in
this series of only 86 patients.
Patients with LD and ED did not have proportional death
hazards and the Cox model therefore had to be stratified
according to disease extent. The number of cases analysed in
this series was regarded insufficient to establish a new
prognostic index.
In conclusion, high levels of NSE and poor performance
are of great importance for predicting the prognosis in
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Figure 2 Scatter diagram of NSE with LDH. Correlation coeffi-
cient r=0.72.
SCLC. Compared to LDH, NSE values were increased in a
greater fraction of our patients and therefore seems to be a
more informative prognostic factor than LDH. It may
therefore be reasonable to suggest that NSE should be
included in future studies of prognostic factors and in
clinical trials on SCLC.
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